Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow (NASDAQ:IMVT) 2026-04-02